Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New wearable gadget aims to give Low-Vision users a helping hand

NCT ID NCT07442461

Symptom relief Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study explores how visual impairment affects movement and daily activities, and tests a wearable system called VIS4ION that provides audio and touch cues to help users navigate. Researchers will enroll 150 adults with visual impairment and healthy controls to see if the device improves task completion, mobility, and physical activity. The goal is to determine if this technology can reduce cognitive load and enhance independence for people with low vision.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VIS4ION Platform (wearable device with bone-conduction headphones and haptic wristband/belt)
What this could lead to
If successful, this device could help people with low vision move around more safely and independently in their daily lives.
What could go wrong
This is an early feasibility study with only 150 participants, so the device may not work well for everyone or in all situations. It is not a treatment for vision loss itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: People with Visual Impairment: * Age between 18 and 80 years. * Diagnosis of visual impairment (any level, any etiology). * Current use of a primary mobility assistive device (e.g., white cane or guide dog). * Ability to travel independently (without assistance from another person). * Capacity to provide informed consent. * Willingness to complete all study-related assessments and procedures Healthy Controls: * Age between 18 and 80 years. * No self-reported visual impairment or use of mobility assistive devices. * Capacity to provide informed consent. * Willingness to complete all study-related assessments and procedures. Exclusion Criteria: * Significant cognitive dysfunction (score \<24 on Folsteins' Mini Mental Status Examination) * Previous neurological illness, complicated medical condition (inclusive of comorbid cognitive impairment) * Significant mobility restrictions; people using walkers and wheelchairs * Pregnancy * Profound auditory impairments (i.e., cannot understand human speech) * Somatosensory impairments to the trunk or torso that precludes use of the haptic interfaces * Significant depression (score \> 11 on the Geriatric Depression scale)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Visual impairment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

vision disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Visual impairment

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • NYU Langone Health

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.